| Uniprot ID | Q02223 |
|---|---|
| Applications | Flow Cyt, MM Tumor cell killing |
| Delivery | In Stock |
| Package | 10μg $99.00 ; 100 μg $438.00 ; 500 μg $1314.00 |
| Formulation & Reconstitution | Powder |
| Tag | |
| Recommended Dilutions | Flow Cyt 1/100; MMTumor cell killing |
| Target | |
| Description | Anti-BCMA bispecific antibody(DM16) |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature. |
| Synonyms | TNFRSF17 |
| Host Species | Rabbit |
| IgG type | Rabbit scfv |
| Clonality | Monoclonal |
| Reactivity | Human |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Buffer | 1XPBS |
| Usage | Research use only |
| Background | BiTE bispecific antibody is an Engineered fusion protein constructed from two single-chain variable fragments (scFvs) of different monoclonal antibodies. One of the scFvs will be constructed from an anti-CD3 monoclonal antibody, and the other scFv fragment which linked by a linker region will be made from an anti-Tumor cell specific monoclonal antibody.The B-cell maturation protein (BCMA or BCM) is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. [provided by RefSeq, Jul 2008] |
Anti-BCMA bispecific antibody(DM16)
Price: 10μg $99.00 ; 100 μg $438.00 ; 500 μg $1314.00
Product Data
Images
Figure 1. The basic principle of BiTE cell killing assay. The BiTE molecule can effectively bring T cells to tumor target cells and stimulate tumor cell killing activity of T cells.
Figure 2. A: The scheme of Anti-BCMA BiTE molecule. B: Tumor cell killing assay. NCI-H929 cells (stably transfected with luciferase), were incubated with freshly isolated human PBMC, and different concentration of BiTE antibodies constructed from rabbit Anti-Human BCMA/TNFRSF17 Clone DM16 (red line), or BB2121 originated huC11D5.3 clone (blue line) or a no BCMA binding clone as negative control (black line). After 48hrs incubation, the viable NCI-H929 tumor cells were measured by luciferase activity assay.